First Tracks Biotherapeutics, Inc. balance sheet TRAX

As of Sep 30, 2026, First Tracks Biotherapeutics, Inc. had total assets of $170.5 million. Stockholders' equity was $151.0 million. It held $155.6 million in cash and investments against $3.8 million of total debt, net cash of $151.9 million. The current ratio, current assets divided by current liabilities, was 9.16.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line
Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Assets
Cash
156
168
248
Short-term investments
0
0
38
Cash and investments
156
168
286
Total current assets
166
178
289
Property and equipment, net
1
1
1
Total assets
170
183
291
Liabilities and equity
Accounts payable
4
3
7
Total current liabilities
18
12
33
Stockholders' equity
151
169
257
Debt
Lease liabilities
4
4
0
Total debt
4
4
0
Net cash
152
164
286
Ratios
Current ratio
9.16x
14.28x
8.74x
Debt to equity
0.02x
0.03x
0.00x
Book value per share
4.21
4.77
—
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
TRAX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
2091349
Former names
Biopharma Company, Inc. (until Feb 6, 2026)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.